1. Recognize the spectrum of rheumatologic immune-related adverse events (IRARs) associated with cancer immunotherapy
2. Differentiate features of rheumatologic IRAEs from "traditional" rheumatic diseases
3. Develop an approach to treatment for rheumatologic IRAEs in collaboration with oncologists
05/16/2017 - 8:30am to 9:30am CDT
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Clifton O. Bingham, M.D.